Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Progression to serious.. -187% Improvement Relative Risk Recovery [data mismatch].. -18% Recovery [data misma.. (b) 6% Viral load, day 14 2% Viral load, day 5 8% c19ivermectin.com Rocha et al. NCT04407507 Ivermectin RCT EARLY TREATMENT Favors ivermectin Favors control
Rocha, 56 patient ivermectin early treatment RCT: 18% worse recovery [p=0.59] and 2% improved viral clearance [p=0.64] https://c19p.org/rocha
copied to clipboard
Ivermectin compared with placebo in the clinical evolution of Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
Rocha et al., Research Square, doi:10.21203/rs.3.rs-1640339/v1 (Preprint)
23 May 2022    Source   PDF   Share   Tweet
Authors did not respond to a request for the data.
Small low-risk patient RCT with 30 low-dose ivermectin and 26 control patients, with no primary outcome events in either arm. Viral load was significantly better with ivermectin on day 5, while there was no significant difference on day 1 or day 14. There was no significant difference in combined symptoms, however authors include cough which was the most frequent symptom and may persist long after infection has been cleared. Ivermectin patients were 4 years older with a higher standard deviation, had higher prevalence of obesity, diabetes, hypertension, and cardiovascular disease, and lower prevalence of hepatic and kidney disease.
External influences may have altered the paper. For example, authors state: "Taken together, these data do not show that ivermectin is effective in the treatment of COVID-19 by "accelerating" viral clearance in the first week, which may translate into a lower rate of complications." Elsewhere, authors note faster viral clearance at day 5, which is usually considered to be a positive result. This sentence may have been modified to be negative, while not fully updating the new sentence to be logical.
Authors report 45.8% asymptomatic placebo patients on day 14, howevere there is no number of 26 patients that is 45.8%. Authors report 18% of ivermectin patients asymptomatic at day 5, however there is no number of 30 patients that is 18%.
risk of progression to serious adverse events, 186.7% higher, RR 2.87, p = 1.00, treatment 1 of 30 (3.3%), control 0 of 26 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no recovery, 17.6% higher, RR 1.18, p = 0.59, treatment 19 of 30 (63.3%), control 14 of 26 (53.8%), day 14, numbers unclear due to data mismatch.
risk of no recovery, 5.8% lower, RR 0.94, p = 0.71, treatment 25 of 30 (83.3%), control 23 of 26 (88.5%), NNT 20, day 5, numbers unclear due to data mismatch.
viral load, 2.4% lower, relative load 0.98, p = 0.64, treatment mean 33.74 (±4.77) n=30, control mean 32.94 (±7.74) n=26, day 14.
viral load, 7.8% lower, relative load 0.92, p = 0.04, treatment mean 30.64 (±3.74) n=30, control mean 28.25 (±4.21) n=26, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rocha et al., 5/23/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Mexico, North America, preprint, 21 authors, dosage 12mg days 1-3, trial NCT04407507.
Contact: arieh.mercado@academicos.udg.mx.
All Studies   Meta Analysis
This PaperIvermectinAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit